Special Considerations in the Management of Autoimmune Hepatitis in COVID-19 Hotspots: A Review
Open Access
- 14 May 2021
- journal article
- review article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000) , 000
Abstract
The ongoing coronavirus disease-2019 (COVID-19) pandemic has necessitated special considerations in the management of diseases. The way presence of pre-existing diseases or treatment for it predisposes to, alters course of, and changes the management of COVID-19, is of relevance and is being extensively studied. Autoimmune hepatitis (AIH) is unique in that it is an autoimmune disease mandating treatment with immunosuppressive drugs, as well as a liver disease with potential for varying degrees of underlying fibrosis. The use of immunosuppressive drugs could alter the risk of acquiring COVID-19, the clinical course and severity of COVID-19 and the degree of underlying liver fibrosis could alter the clinical outcomes of patients with COVID-19. In this review, we try to summarize key areas relevant in understanding and improving the clinical care of patients with AIH in the current pandemic. Special considerations required in the management of patients with AIH in COVID-19 hotspots have been outlined based on the current evidence.Keywords
This publication has 83 references indexed in Scilit:
- Suppression of Coronavirus Replication by Cyclophilin InhibitorsViruses, 2013
- Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remissionJournal of Hepatology, 2013
- Response to Vaccination Against Hepatitis B Virus with a Schedule of Four 40-μg Doses in Cirrhotic Patients Evaluated for Liver Transplantation: Factors Associated with a ResponseTransplantation Proceedings, 2012
- Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506Virus Research, 2012
- The SARS-Coronavirus-Host Interactome: Identification of Cyclophilins as Target for Pan-Coronavirus InhibitorsPLOS Pathogens, 2011
- Budesonide Induces Remission More Effectively Than Prednisone in a Controlled Trial of Patients With Autoimmune HepatitisGastroenterology, 2010
- Replicating and non-replicating viral vectors for vaccine developmentCurrent Opinion in Biotechnology, 2007
- Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesisThe Journal of Pathology, 2004
- Immunogenicity of Hepatitis A Vaccination in Decompensated Cirrhotic PatientsHepatology, 2001
- CONTROLLED TRIAL OF PREDNISONE AND AZATHIOPRINE IN ACTIVE CHRONIC HEPATITISThe Lancet, 1973